{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:59:03Z","timestamp":1792051143410,"version":"4.4.0"},"reference-count":67,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007216","type":"journal-article","created":{"date-parts":[[2008,6,30]],"date-time":"2008-06-30T13:04:46Z","timestamp":1214831086000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis"],"prefix":"10.1002","author":[{"given":"Daniel C","family":"Baumgart","sequence":"first","affiliation":[{"name":"Charit\u00e9 Medical Center, Virchow Hospital ; Department of Medicine, Division of Gastroenterology & Hepatology ; Medical School of the Humboldt-University Augustenburger Platz 1 Berlin Germany 13353"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Robarts Research Institute; Robarts Clinical Trials; P.O. Box 5015 100 Perth Drive London Ontario Canada N6A 5K8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Feagan","sequence":"additional","affiliation":[{"name":"Robarts Research Institute; Robarts Clinical Trials; P.O. Box 5015 100 Perth Drive London Ontario Canada N6A 5K8"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,7,16]]},"reference":[{"issue":"9","key":"10.1002\/14651858.CD007216-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/gut.2005.081794","article-title":"A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis","volume":"55","author":"Ogata","year":"2006","journal-title":"Gut"},{"issue":"11","key":"10.1002\/14651858.CD007216-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1136\/gut.2005.081794corr1","article-title":"Correction: A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis","volume":"55","author":"Ogata","year":"2006","journal-title":"Gut"},{"issue":"10","key":"10.1002\/14651858.CD007216-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1046\/j.1365-2036.2003.01534.x","article-title":"Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease","volume":"17","author":"Baumgart","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1002\/14651858.CD007216-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/00054725-200407000-00014","article-title":"Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus (FK506) in ulcerative colitis","volume":"10","author":"Baumgart","year":"2004","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"10.1002\/14651858.CD007216-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1136\/gut.2005.078972","article-title":"Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis","volume":"54","author":"Baumgart","year":"2005","journal-title":"Gut"},{"issue":"5","key":"10.1002\/14651858.CD007216-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1572-0241.2006.00524.x","article-title":"Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up","volume":"101","author":"Baumgart","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1002\/14651858.CD007216-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ibd.20263","article-title":"Efficacy and safety of tacrolimus in refractory colitis and Crohn's disease: a single-center experience","volume":"14","author":"Benson","year":"2008","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"10.1002\/14651858.CD007216-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00005176-199610000-00023","article-title":"Tacrolimus (FK-506) treatment of fulminant colitis in a child","volume":"23","author":"Bousvaros","year":"1996","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"6","key":"10.1002\/14651858.CD007216-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1067\/mpd.2000.109193","article-title":"Oral tacrolimus treatment of severe colitis in children","volume":"137","author":"Bousvaros","year":"2000","journal-title":"J Pediatr"},{"issue":"7","key":"10.1002\/14651858.CD007216-BIB0010|cit10","first-page":"465","article-title":"Immunodulation with tacrolimus (FK506): results of a prospective, open-label, non-controlled trial in patients with inflammatory bowel disease","volume":"95","author":"de","year":"2003","journal-title":"Rev Esp Enferm Dig"},{"issue":"10","key":"10.1002\/14651858.CD007216-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1111\/j.1572-0241.1998.539_g.x","article-title":"Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506)","volume":"93","author":"Fellermann","year":"1998","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1002\/14651858.CD007216-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/PL00002176","article-title":"[Sweet syndrome and erythema nodosum in ulcerative colitis, refractory to steroids: successful treatment with tacrolimus]","volume":"96","author":"Fellermann","year":"2001","journal-title":"Med Klin (Munich)"},{"issue":"5","key":"10.1002\/14651858.CD007216-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00054725-200209000-00002","article-title":"Response of refractory colitis to intravenous or oral tacrolimus (FK506)","volume":"8","author":"Fellermann","year":"2002","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1002\/14651858.CD007216-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1365-2036.2003.01662.x","article-title":"Effect of oral tacrolimus (FK 506) on steroid-refractory moderate\/severe ulcerative colitis","volume":"18","author":"Hogenauer","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1002\/14651858.CD007216-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/00004836-200003000-00015","article-title":"Oral tacrolimus (FK 506) in Crohn's disease complicated by fistulae of the perineum","volume":"30","author":"Ierardi","year":"2000","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"10.1002\/14651858.CD007216-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1046\/j.1365-2036.2001.00938.x","article-title":"Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance","volume":"15","author":"Ierardi","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1002\/14651858.CD007216-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/S0041-1345(01)01964-9","article-title":"Long-term tacrolimus: a promising therapeutic approach for Crohn's disease","volume":"33","author":"Ierardi","year":"2001","journal-title":"Transplant Proc"},{"issue":"8","key":"10.1002\/14651858.CD007216-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s005350070065","article-title":"Tacrolimus in corticosteroid-resistant ulcerative colitis","volume":"35","author":"Matsuhashi","year":"2000","journal-title":"J Gastroenterol"},{"issue":"2","key":"10.1002\/14651858.CD007216-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ibd.20052","article-title":"Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease","volume":"13","author":"Ng","year":"2007","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"10.1002\/14651858.CD007216-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00384-002-0458-8","article-title":"Rescue therapy with tacrolimus in a patient with toxic megacolon","volume":"18","author":"Pascu","year":"2003","journal-title":"Int J Colorectal Dis"},{"issue":"3","key":"10.1002\/14651858.CD007216-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/MPG.0b013e31805b82e4","article-title":"Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children","volume":"45","author":"Ziring","year":"2007","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"10.1002\/14651858.CD007216-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0022-3565(24)36473-0","article-title":"Effects of cyclosporine or FK506 in chronic colitis","volume":"280","author":"Aiko","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1002\/14651858.CD007216-BIB0023|cit23","unstructured":"Alderson P Green S Higgens JPT Assessment of study quality. Cochrane Reviewers' Handbook 4.2.2 [updated December 2003]; Section 6. In: The Cochrane Library, Issue 1, 2004 Chichester UK: John Wiley & Sons, Ltd"},{"key":"10.1002\/14651858.CD007216-BIB0024|cit24","first-page":"1098","article-title":"Prograf (Tacrolimus) full prescribing information","volume-title":"Physician's desk reference","author":"Astellas","year":"2007"},{"issue":"Suppl VII","key":"10.1002\/14651858.CD007216-BIB0025|cit25","first-page":"A57","article-title":"The phase I\/II visilizumab study. A report of safety and efficacy of treatment and retreatment in ulcerative colitis patients refractory to treatment with i.v. steroids (IVSR-UC)","volume":"54","author":"Baumgart","year":"2005","journal-title":"Gut"},{"issue":"9573","key":"10.1002\/14651858.CD007216-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(07)60751-X","article-title":"Inflammatory bowel disease: clinical aspects and established and evolving therapies","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"issue":"9573","key":"10.1002\/14651858.CD007216-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(07)60750-8","article-title":"Inflammatory bowel disease: cause and immunobiology","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD007216-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0022-3468(00)90027-7","article-title":"Composite liver--small bowel allografts with preservation of donor duodenum and hepatic biliary system in children","volume":"35","author":"Bueno","year":"2000","journal-title":"J Pediatr Surg"},{"issue":"1","key":"10.1002\/14651858.CD007216-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1074\/jbc.274.1.93","article-title":"Characterization of calcineurin in human neutrophils. Inhibitory effect of hydrogen peroxide on its enzyme activity and on NF-kappaB DNA binding","volume":"274","author":"Carballo","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1002\/14651858.CD007216-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"V1","DOI":"10.1136\/gut.2004.043372","article-title":"Guidelines for the management of inflammatory bowel disease in adults","volume":"53 Suppl 5","author":"Carter","year":"2004","journal-title":"Gut"},{"issue":"1","key":"10.1002\/14651858.CD007216-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1046\/j.1365-2036.2003.01639.x","article-title":"Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis","volume":"18","author":"Creed","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1002\/14651858.CD007216-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1053\/gast.2001.23983","article-title":"Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis","volume":"120","author":"D'Haens","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD007216-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.gastro.2006.12.038","article-title":"A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis","volume":"132","author":"D'Haens","year":"2007","journal-title":"Gastroenterology"},{"issue":"24","key":"10.1002\/14651858.CD007216-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa042982","article-title":"Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin","volume":"352","author":"Feagan","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1002\/14651858.CD007216-BIB0035|cit35","first-page":"1098","article-title":"Prograf\u00ae (Tacrolimus) Full Prescribing Information","volume-title":"Physician's Desk Reference","author":"Fujisawa Healthcare Inc","year":"2002"},{"issue":"4","key":"10.1002\/14651858.CD007216-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.4049\/jimmunol.162.4.1988","article-title":"Fas ligand induction in human NK cells is regulated by redox through a calcineurin-nuclear factors of activated T cell-dependent pathway","volume":"162","author":"Furuke","year":"1999","journal-title":"J Immunol"},{"issue":"4","key":"10.1002\/14651858.CD007216-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1046\/j.1365-2036.2002.01205.x","article-title":"A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin","volume":"16","author":"Gordon","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"issue":"5 Suppl 6","key":"10.1002\/14651858.CD007216-BIB0038|cit38","first-page":"4","article-title":"Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis","volume":"19","author":"Goto","year":"1987","journal-title":"Transplant Proc"},{"issue":"3","key":"10.1002\/14651858.CD007216-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1053\/j.gastro.2007.02.008","article-title":"Tacrolimus for active ulcerative colitis? Yes! (even though Cochrane says \"no\")","volume":"132","author":"Hibi","year":"2007","journal-title":"Gastroenterology"},{"issue":"1-3","key":"10.1002\/14651858.CD007216-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0014-2999(93)90990-Y","article-title":"Attenuation of epithelial injury in acute experimental colitis by immunomodulators","volume":"239","author":"Higa","year":"1993","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1002\/14651858.CD007216-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2036.1995.tb00385.x","article-title":"Effects of FK506 on an experimental model of colitis in rats","volume":"9","author":"Hoshino","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1002\/14651858.CD007216-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"issue":"3","key":"10.1002\/14651858.CD007216-BIB0043|cit43","first-page":"1609","article-title":"FK 506 in small bowel transplant recipients: pharmacokinetics and dosing","volume":"26","author":"Jain","year":"1994","journal-title":"Transplant Proc"},{"key":"10.1002\/14651858.CD007216-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","article-title":"Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study","volume":"128","author":"Jarnerot","year":"2005","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD007216-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.7164\/antibiotics.40.1249","article-title":"FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics","volume":"40","author":"Kino","year":"1987","journal-title":"J Antibiot (Tokyo)"},{"issue":"9","key":"10.1002\/14651858.CD007216-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.7164\/antibiotics.40.1256","article-title":"FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro","volume":"40","author":"Kino","year":"1987","journal-title":"J Antibiot (Tokyo)"},{"issue":"5 Suppl 6","key":"10.1002\/14651858.CD007216-BIB0047|cit47","first-page":"36","article-title":"Effect of FK-506 on human mixed lymphocyte reaction in vitro","volume":"19","author":"Kino","year":"1987","journal-title":"Transplant Proc"},{"issue":"7","key":"10.1002\/14651858.CD007216-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1572-0241.2004.40036.x","article-title":"Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee","volume":"99","author":"Kornbluth","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1002\/14651858.CD007216-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0016-5085(94)90054-X","article-title":"Course of ulcerative colitis: analysis of changes in disease activity over years","volume":"107","author":"Langholz","year":"1994","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD007216-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3109\/00365529609004876","article-title":"Changes in extent of ulcerative colitis: a study on the course and prognostic factors","volume":"31","author":"Langholz","year":"1996","journal-title":"Scand J Gastroenterol"},{"key":"10.1002\/14651858.CD007216-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2165\/00003088-200140060-00006","article-title":"Pharmacokinetics of cyclosporin microemulsion in patients with inflammatory bowel disease","volume":"40","author":"Latteri","year":"2001","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1002\/14651858.CD007216-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1053\/j.gastro.2006.01.048","article-title":"American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease","volume":"130","author":"Lichtenstein","year":"2006","journal-title":"Gastroenterology"},{"issue":"26","key":"10.1002\/14651858.CD007216-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","article-title":"Cyclosporine in severe ulcerative colitis refractory to steroid therapy","volume":"330","author":"Lichtiger","year":"1994","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1002\/14651858.CD007216-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00054725-199911000-00001","article-title":"Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae","volume":"5","author":"Lowry","year":"1999","journal-title":"Inflamm Bowel Dis"},{"key":"10.1002\/14651858.CD007216-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0889-8553(21)00055-8","article-title":"Immunosuppressants","volume":"21","author":"Marsh","year":"1992","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1002\/14651858.CD007216-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1080\/003655201750163051","article-title":"Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis","volume":"36","author":"Navazo","year":"2001","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"10.1002\/14651858.CD007216-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1152\/physrev.2000.80.4.1483","article-title":"Calcineurin: form and function","volume":"80","author":"Rusnak","year":"2000","journal-title":"Physiol Rev"},{"issue":"5","key":"10.1002\/14651858.CD007216-BIB0058|cit58","first-page":"876","article-title":"Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease","volume":"92","author":"Sandborn","year":"1997","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1002\/14651858.CD007216-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0016-5085(03)00877-1","article-title":"Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial","volume":"125","author":"Sandborn","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD007216-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1002\/14651858.CD007216-BIB0061|cit61","article-title":"Cyclosporine A for induction of remission in severe ulcerative colitis","author":"Shibolet","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007216-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/0016-5085(87)90621-4","article-title":"5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis","volume":"92","author":"Sutherland","year":"1987","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD007216-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000201253","article-title":"Activated immunocompetent cells in rat colitis mucosa induced by dextran sulfate sodium and not complete but partial suppression of colitis by FK506","volume":"56","author":"Takizawa","year":"1995","journal-title":"Digestion"},{"issue":"3","key":"10.1002\/14651858.CD007216-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1053\/j.gastro.2007.02.007","article-title":"Tacrolimus for active ulcerative colitis? Yes! (even though Cochrane says \"no\")","volume":"132","author":"Ullman","year":"2007","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD007216-BIB0065|cit65","first-page":"1025","article-title":"Randomized, double-blind comparison of 4 mg\/kg versus 2 mg\/kg intravenous cyclosporine in severe ulcerative colitis","volume":"125","author":"Assche","year":"2003","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD007216-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1053\/j.gastro.2003.09.036","article-title":"Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County","volume":"125","author":"Winther","year":"2003","journal-title":"Gastroenterology"},{"issue":"1-2","key":"10.1002\/14651858.CD007216-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0009-8981(01)00678-7","article-title":"Therapeutic drug monitoring for immunosuppressants","volume":"313","author":"Wong","year":"2001","journal-title":"Clin Chim Acta"}],"updated-by":[{"DOI":"10.1002\/14651858.cd007216.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD007216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T22:07:22Z","timestamp":1738274842000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD007216"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2008,7,16]]},"references-count":67,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007216","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,16]]}}}